UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT ~~Pursuant to Section 13 OR 15(d) of the~~ ~~Securities Exchange Act of 1934~~

~~Date~~ Pursuant ofto ~~Report~~Section 13 or 15(~~Date~~d) of ~~earliest~~the ~~event~~Securities ~~reported)~~Exchange ~~March 13,~~Act ~~2009~~of 1934

~~DATATRAK~~Date ~~International~~of Report (Date of Earliest Event Reported): May 29, ~~Inc.~~ 2009

Ohio		001-33688		34-1685364
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

DATATRAK International, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

Ohio	000-20699	34-1685364
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
6150 Parkland Boulevard, Mayfield Hts., Ohio		44124
(Address of Principal Executive Offices)		(Zip Code)
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: 440-443-0082

Not Applicable ______________________________________________ Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:

o [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~o Soliciting~~ Top ~~material~~of ~~pursuant to Rule 14a-12 under~~ the ~~Exchange Act (17 CFR 240.14a-12)~~Form

~~o Pre-commencement~~ Item ~~communications~~3.01 ~~pursuant~~Notice of Delisting or Failure to ~~Rule 14d-2(b)~~Satisfy ~~under~~a ~~the~~Continued ~~Exchange~~Listing ~~Act~~Rule ~~(17~~or ~~CFR 240~~Standard; Transfer of Listing.~~14d-2(b))~~

~~o Pre-commencement~~ On ~~communications~~June ~~pursuant~~2, 2009, DATATRAK International, Inc. (the "Company") received notice that the Nasdaq Hearings Panel (the "Panel") has determined to ~~Rule 13e-~~delist the Company’s common shares from the Nasdaq Capital Market and will suspend trading of the Company’s securities effective at the open of trading on June 4, 2009. As previously disclosed, on August 18, 2008, the Company received a notice (the "Stockholders’ Equity Notice") from the Nasdaq Stock Market ("Nasdaq") indicating the Company was not in compliance with Marketplace Rule 4310(c)(3) (the "Minimum Equity Rule"), which requires the Company to have a minimum of $2,500,000 in stockholders’ equity or $35,000,000 market value of listed securities or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years. Nasdaq requested in the Stockholders’ Equity Notice that the Company submit a plan to regain compliance under the ~~Exchange~~Minimum ~~Act~~Equity ~~(17~~Rule ~~CFR 240~~on or before September 3, 2008.~~13e~~ The Company subsequently submitted a proposal to Nasdaq outlining its plan to achieve and sustain compliance with the Minimum Equity Rule and requested an extension of time in order to execute its proposal. On December 2, 2008, the Company received a letter from Nasdaq informing it that the Nasdaq staff could not provide the Company with additional time to regain compliance with the Minimum Equity Rule, and unless the Company filed an appeal to the Nasdaq staff’s determination, the Company’s common shares would be suspended at the opening of business on December 11, 2008 and a Form 25-NSE would be filed with the SEC which would remove the Company common shares from listing and registration on Nasdaq. On December 9, 2008, the Company filed a request for a hearing in front of the Panel to appeal the Nasdaq staff’s determination pursuant to the procedures set forth in the Nasdaq Marketplace Rule 4800 Series. This request stayed the suspension of the Company’s common shares and the filing of the Form 25-NSE pending the decision. On January 8, 2009, the Company presented its plan to regain compliance with the Minimum Equity Rule and all other applicable requirements for continued listing on the Nasdaq to the Panel, and requested an exception until June 1, 2009 by which date the Company believes that it will be able to demonstrate such compliance.The Panel’s decision to delist the securities of the Company from Nasdaq was based on its conclusion that the Company had not met the exception requirement and that it remains deficient with respect to the Minimum Equity Rule. The Company will not appeal the Panel’s decision.The Company has been advised by Pink OTC Markets Inc, which operates an electronic quotation service for securities traded over-the-counter, that its securities are immediately eligible for quotation effective with the open of business on June 4, 2009. The Company’s common shares will continue to trade under the symbol DATA.The Company’s common shares may, in the future, also be quoted on the Over-the-Counter Bulletin Board (cthe "OTCBB"), an electronic quotation service maintained by the Financial Industry Regulatory Authority ("FINRA"), provided that a market maker in the Company’s common shares files the appropriate application with, and such application is cleared by, FINRA. The Company anticipates disclosing further trading venue information for its common shares once such information becomes available.The Company issued a press release today announcing the Nasdaq determination, a copy of which is attached hereto as Exhibit 99.1.

Item 2 5.02. ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On (e) Termination of Salary Continuation Payments to G. Matthew DelaneyAs previously disclosed, effective March 16 13, 2009, ~~DATATRAK~~the ~~International,~~Board ~~Inc~~of Directors removed G. (Matthew Delaney as the “Company”)’s ~~issued~~Interim aPresident ~~press~~and ~~release~~terminated ~~relating~~the to employment agreement between Mr. Delaney and the Company’s ~~earnings~~dated ~~for~~as of May 15, 2008 (the ~~three~~"Employment ~~months~~Agreement"). As a result, commencing on April 13, 2009 and ~~fiscal~~pursuant to the terms of the Employment Agreement, Mr. Delaney was, among other things, entitled to receive one (1) year ~~ended~~of ~~December 31~~salary continuation subject to the terms and conditions of the Employment Agreement.By letter dated May 29, ~~2008~~2009, the Company notified Mr. ADelaney ~~copy~~that it had become aware that Mr. Delaney had violated certain covenants of the ~~press~~ ~~release~~Employment isAgreement ~~attached~~and toaccordingly, ~~this~~the ~~report~~Company aswas ~~Exhibit 99~~terminating the remaining salary continuation payments due under the Employment Agreement effective immediately.1 Mr. Delaney remains subject to the confidentiality, non-competition, non-interference and non-disparagement provisions of his Employment Agreement.

Item 5 9.~~02.~~01 ~~Departure~~Financial ofStatements ~~Directors~~and ~~or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Exhibits.

(bc) ~~Removal of G~~ Exhibits99.1 Press ~~Matthew~~release ~~Delaney~~dated asJune ~~Interim~~4, ~~President~~2009.

~~Effective March 13, 2009, the Board of Directors removed G. Matthew Delaney as the Company’s~~ ~~Interim President and terminated the employment agreement between Mr. Delaney and the Company dated~~ ~~as of May 15, 2008 (the “Employment Agreement”). As a result, effective April 12, 2009, Mr. Delaney~~ ~~will~~ Top ~~no longer be employed by the Company. Pursuant to the terms~~ of the ~~Employment Agreement, Mr.~~Form ~~Delaney will receive one (1) year of salary continuation commencing on April 13, 2009 and up to~~ ~~$10,000 in outplacement services from an agency to be selected by the Company.~~

Effective March 13, 2009, the Board appointed Laurence P. Birch as Interim President. Mr. Birch will continue to serve as the Chairman of the Board of Directors and the Interim Chief Executive Officer in addition to his service as Interim President.

Mr. Birch has served on the Board since April 16, 2007, as chairman of the Board since May 15, 2008 and was appointed Interim Chief Executive Officer effective January 21, 2009. The information regarding Mr. Birch required under Items 401(b), (d) and (e) of Regulation S-K is included under the heading “Item 4A. Executive Officers of the Company” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2009, and is incorporated herein by reference.

There is no arrangement or understanding between Mr. Birch and any other person pursuant to which Mr. Birch was appointed as Interim President. There are no transactions in which Mr. Birch has an interest that are required to be disclosed under Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits

99.1 Press release dated March 16, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DATATRAK INTERNATIONAL, INC.
		DATATRAK International, Inc.
Date March 18, 2009
June 4, 2009		By:	/s/ Raymond J. Merk
	By	/s/ Raymond J. Merk
			Name: Raymond J. Merk
		Raymond J. Merk
			Title: Vice President of Finance, Chief Financial Officer, Chief Operating Officer and Treasurer
		Vice President of Finance, Chief Financial Officer, Chief Operating Officer and Treasurer

~~EXHIBIT~~ Top ~~INDEX~~of the Form

Exhibit No.		Description
99.1		Press release dated March 16, 2009

Exhibit Index

Certain statements made in this Form 8-K, other SEC filings or written materials or orally made by the Company or its representatives may constitute forward-looking statements that are based on management’s current beliefs, estimates and assumptions concerning the operations, future results and prospects of the Company and the clinical pharmaceutical research industry in general. All statements that address operating performance, events or developments that management anticipates will occur in the future, including statements related to future revenue, profits, expenses, cost reductions, cash management alternatives, restructuring our debt, raising additional funds, income and earnings per share or statements expressing general optimism about future results, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). In addition, words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” variations of such words, and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the safe harbors created in the Exchange Act. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company’s performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company’s quarterly results; the viability of the Company’s business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company’s dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other’s intellectual property rights; delisting of the Company’s common shares from the Nasdaq due to our failure to continue to meet applicable Nasdaq Capital Market requirements; the Company’s success in integrating ClickFind’s operations into its own operations and the costs associated with maintaining and developing two product suites; the effects and outcomes of the Company’s exploration of potential opportunities directed at maximizing shareholder value; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all inclusive. In addition, the Company’s success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. Any forward-looking statement speaks only as of the date on which such statement is made and the Company does not undertake any obligation to update any statements whether as a result of new information, future events or otherwise.


Exhibit No.		Description

99.1		Press release dated June 4, 2009

The information set forth in Item 2.02 in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference to such filing.

Filing Compare · DATATRAK INTERNATIONAL INC